Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
March 20, 2025 19:11 ET
|
Novartis Pharma AG
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one...
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
March 19, 2025 09:00 ET
|
Novartis Pharma AG
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA Treatment with investigational OAV101 IT...
Aktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrats gut
March 07, 2025 09:11 ET
|
Novartis Pharma AG
Die Aktionärinnen und Aktionäre genehmigten die 28. Dividendenerhöhung in Folge. Für 2024 wird die Dividende auf CHF 3.50 (+6,1%) je Aktie erhöht, was einer Rendite von 3,5% entspricht1Die...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
March 07, 2025 09:11 ET
|
Novartis Pharma AG
Shareholders approved 28th consecutive dividend increase to CHF 3.50 (+6.1%) per share for 2024, representing a 3.5% yield¹ Shareholders elected Giovanni Caforio as new member and Chair of the Board...
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
February 28, 2025 09:00 ET
|
Novartis Pharma AG
Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presentedNew analyses of 52-week data from Phase III...
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
February 28, 2025 07:39 ET
|
Novartis Pharma AG
If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5 ...
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
February 11, 2025 01:15 ET
|
Novartis Pharma AG
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in...
Novartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen
January 31, 2025 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KRGeschäftsjahrDer Nettoumsatz wuchs um +12% (kWk1, +11% USD), das operative Kernergebnis1 verbesserte sich um +22% (kWk, +19% USD)Das Umsatzwachstum beruhte...
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
January 31, 2025 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from...
Novartis Entresto® US patent upheld by US Court of Appeals
January 13, 2025 01:15 ET
|
Novartis Pharma AG
Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto® (sacubitril/valsartan) combination...